TargetMol

Amuvatinib

Product Code:
 
TAR-T2516
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T2516-1mg1mg£106.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2516-2mg2mg£120.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2516-5mg5mg£145.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2516-1mL1 mL * 10 mM (in DMSO)£152.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2516-10mg10mg£191.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2516-25mg25mg£291.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2516-50mg50mg£425.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2516-100mg100mg£517.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Amuvatinib is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.
CAS:
850879-09-3
Formula:
C23H21N5O3S
Molecular Weight:
447.51
Pathway:
Apoptosis; DNA Damage/DNA Repair; Cell Cycle/Checkpoint; Tyrosine Kinase/Adaptors; Angiogenesis
Purity:
0.9954
SMILES:
S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12
Target:
Apoptosis; FLT; c-Met/HGFR; c-RET; DNA/RNA Synthesis; PDGFR; c-Kit

References

2. Hurley LH, et al. World Patent, WO/2005/037825. 3. Mahadevan D, et al. Oncogene, 2007, 26(27), 3909-3919. 4. Qi W, et al. BMC Cancer, 2009, 9, 142. 5. Welsh JW, et al. Radiat Oncol, 2009, 4, 69. 6. Han H W, Hahn S, Jeong H Y, et al. LINCS L1000 dataset-based repositioning of CGP-60474 as a highly potent anti-endotoxemic agent[J]. Scientific reports. 2018 Oct 8;8(1):14969.